Agilent Technologies Inc. (NYSE: A) today introduced a high-performance ion trap mass spectrometer (MS) that allows pharmaceutical and academic life-science researchers to identify 60 to 80 percent more peptides than preceding models in proteomics applications, such as protein identification and biomarker discovery, potentially leading to a better understanding of diseases like cancer and speeding drug development efforts. The Agilent 1100 Series LC/MSD Trap XCT Ultra offers significantly improved scan cycle times, enabling collection of mass spectra at rates up to three times faster than its predecessors.
"The combination of the new LC/MSD Trap XCT Ultra with Agilent's breakthrough HPLC-Chip/MS technology will set a new standard for protein identification and analytical performance," said Ken Imatani, product marketing manager for Agilent's ion trap mass spectrometers. "The high resolution, scan speed and sensitivity of the LC/MSD Trap XCT Ultra make it a powerful tool for a wide range of qualitative applications in which high performance and productivity are essential, particularly in proteomics research."
"The LC/MSD Trap XCT Ultra is the latest example of Agilent's integrated approach to facilitating proteomics research, enabling researchers to solve their most challenging scientific questions more easily and with greater confidence," said Taia Ergueta, general manager of Agilent's Proteomics and LC/MS business. "The LC/MSD Trap XCT Ultra improves performance for a wide range of demanding applications in metabolite characterization, natural products screening, product degradation studies and food and environmental analysis, which require excellent sensitivity and fast scanning capability."
The LC/MSD Trap XCT Ultra, which is based on an advanced multipole ion trap technology, has a full-scan MS/MS sensitivity specification of 250 femtograms for reserpine. The system also has two new data-dependent neutral-loss analysis modes that provide ePage: 1 2 Related biology news :1
. Products containing specific probes for detecting alternative splice forms protected2
. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping3
. Production of key Alzheimers protein monitored for first time in humans4
. Stem cell treatment improves mobility after spinal cord injury5
. Combination therapy improves AIDS-related lymphoma outcome6
. One fish, two fish: New MIT sensor improves fish counts7
. Man-made heart tissue improves cardiac performance8
. Viagra improves high altitude exercise performance up to 45% for some9
. Quitting smoking improves lung function considerably10
. Melatonin improves mood in winter depression11
. Brain protein improves stroke symptoms in rats, even when injected after 3 days